Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development / Rachel Glennerster, Thomas Kelly, Claire T. McMahon, Christopher M. Snyder
A booster of the COVID-19 vaccine targeting the prevailing Omicron variant did not become available in the United States until a year after the variant was first detected. This pattern of developing, testing, and distributing a variant-specific booster may become the default response to further waves of COVID-19 caused by new variants. An innovation with realistic scientific potential--a universal COVID-19 vaccine, effective against existing and future variants--could provide much more value by preempting new variants. Averaged across Monte Carlo simulations, we estimate the incremental value to the U.S. population of a universal COVID-19 vaccine to be $1.5-$2.6 trillion greater than variant-specific boosters (depending on how the arrival rate of variants is modeled). This social value eclipses the cost of an advance market commitment to incentivize the universal vaccine by several orders of magnitude.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
January 2024 |
|---|---|
| Erschienen: |
Cambridge, Mass: National Bureau of Economic Research ; January 2024 |
| Reihe: |
NBER working paper series - no. w32059 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Glennerster, Rachel, 1965- [VerfasserIn] |
|---|---|
| Körperschaft: |
National Bureau of Economic Research [Herausgebendes Organ] |
| Links: |
www.nber.org [lizenzpflichtig] |
|---|
| Themen: |
Chemicals; Rubber; Drugs; Biotechnology; Plastics |
|---|
| Umfang: |
1 Online-Ressource ; illustrations (black and white) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1880205653 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1880205653 | ||
| 003 | DE-627 | ||
| 005 | 20240312093322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xxu|||||o 00| ||eng c | ||
| 035 | |a (DE-627)1880205653 | ||
| 035 | |a (DE-599)KEP100458971 | ||
| 035 | |a (OCoLC)1420299776 | ||
| 035 | |a (NBER)w32059 | ||
| 035 | |a (EBP)100458971 | ||
| 040 | |a DE-627 |b eng |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XD-US | ||
| 084 | |a H51 |2 jelc | ||
| 084 | |a I18 |2 jelc | ||
| 084 | |a L65 |2 jelc | ||
| 100 | 1 | |a Glennerster, Rachel |d 1965- |e verfasserin |0 (DE-588)130514845 |0 (DE-627)503033715 |0 (DE-576)298242257 |4 aut | |
| 245 | 1 | 0 | |a Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development |c Rachel Glennerster, Thomas Kelly, Claire T. McMahon, Christopher M. Snyder |
| 264 | 1 | |a Cambridge, Mass |b National Bureau of Economic Research |c January 2024 | |
| 300 | |a 1 Online-Ressource |b illustrations (black and white) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a NBER working paper series |v no. w32059 | |
| 520 | |a A booster of the COVID-19 vaccine targeting the prevailing Omicron variant did not become available in the United States until a year after the variant was first detected. This pattern of developing, testing, and distributing a variant-specific booster may become the default response to further waves of COVID-19 caused by new variants. An innovation with realistic scientific potential--a universal COVID-19 vaccine, effective against existing and future variants--could provide much more value by preempting new variants. Averaged across Monte Carlo simulations, we estimate the incremental value to the U.S. population of a universal COVID-19 vaccine to be $1.5-$2.6 trillion greater than variant-specific boosters (depending on how the arrival rate of variants is modeled). This social value eclipses the cost of an advance market commitment to incentivize the universal vaccine by several orders of magnitude | ||
| 530 | |a Hardcopy version available to institutional subscribers | ||
| 533 | |n Hardcopy version available to institutional subscribers | ||
| 650 | 7 | |8 1.1\x |a Coronavirus |0 (DE-627)1694209695 |0 (DE-2867)30218-4 |2 stw | |
| 650 | 7 | |8 1.2\x |a Impfung |0 (DE-627)091366755 |0 (DE-2867)19526-2 |2 stw | |
| 650 | 7 | |8 1.3\x |a Arzneimittel |0 (DE-627)091383145 |0 (DE-2867)14728-1 |2 stw | |
| 650 | 7 | |8 1.4\x |a Gesundheitsversorgung |0 (DE-627)091363411 |0 (DE-2867)18891-5 |2 stw | |
| 650 | 7 | |8 1.5\x |a Soziale Werte |0 (DE-627)091390052 |0 (DE-2867)16642-1 |2 stw | |
| 650 | 7 | |8 1.6\x |a USA |0 (DE-627)091396867 |0 (DE-2867)17829-1 |2 stw | |
| 650 | 4 | |a Government Expenditures and Health | |
| 650 | 4 | |a Government Policy; Regulation; Public Health | |
| 650 | 4 | |a Chemicals; Rubber; Drugs; Biotechnology; Plastics | |
| 700 | 1 | |a Kelly, Thomas |e verfasserin |0 (DE-588)1319350461 |0 (DE-627)188072927X |4 aut | |
| 700 | 1 | |a McMahon, Claire T. |e verfasserin |0 (DE-588)131935078X |0 (DE-627)1880729717 |4 aut | |
| 700 | 1 | |a Snyder, Christopher M. |e verfasserin |0 (DE-588)128651539 |0 (DE-627)376951370 |0 (DE-576)276531388 |4 aut | |
| 710 | 2 | |a National Bureau of Economic Research |e Herausgebendes Organ |0 (DE-588)39157-8 |0 (DE-627)100894720 |0 (DE-576)190363584 |4 isb | |
| 856 | 4 | 0 | |u https://www.nber.org/papers/w32059 |m X:NBER |x Verlag |z lizenzpflichtig |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3386/w32059 |m X:NBER |x Resolving-System |z lizenzpflichtig |
| 912 | |a ZDB-194-NBW | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_22_i26103 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a ISIL_DE-206 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a ISIL_DE-705 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a ISIL_DE-89 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a ISIL_DE-14 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 4482194255 |h OLR-ZDB-194-NBW |y zi26103 |z 10-02-24 | ||
| 980 | |2 26 |1 01 |x 0206 |b 4482195979 |h OLR-NBW |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y znz |z 10-02-24 | ||
| 980 | |2 60 |1 01 |x 0705 |b 4482192805 |h NBER |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |k Nur für Angehörige der HSU: Volltextzugang von außerhalb des Campus mit Anmeldung über Shibboleth mit Ihrer Bibliothekskennung |y z |z 10-02-24 | ||
| 980 | |2 70 |1 01 |x 0089 |b 448219512X |h OLR-NBER |k Campusweiter Zugriff (Universität Hannover). - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 10-02-24 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 4479729895 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Universitätslizenz |y l01 |z 08-02-24 | ||
| 980 | |2 2006 |1 01 |x DE-14 |b 4479722807 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-02-24 | ||
| 981 | |2 22 |1 01 |x 0018 |y Volltextzugang Campus |r http://dx.doi.org/10.3386/w32059 | ||
| 981 | |2 22 |1 01 |x 0018 |y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus |r http://emedien.sub.uni-hamburg.de/han/nber/dx.doi.org/10.3386/w32059 | ||
| 981 | |2 26 |1 01 |x 0206 |r http://dx.doi.org/10.3386/w32059 | ||
| 981 | |2 60 |1 01 |x 0705 |r http://dx.doi.org/10.3386/w32059 | ||
| 981 | |2 70 |1 01 |x 0089 |r http://dx.doi.org/10.3386/w32059 | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.redi-bw.de/start/unifr/NBER-online/10.3386/w32059 | ||
| 981 | |2 2006 |1 01 |x DE-14 |r http://dx.doi.org/10.3386/w32059 | ||
| 995 | |2 22 |1 01 |x 0018 |a OLR-ZDB-194-NBW | ||
| 995 | |2 26 |1 01 |x 0206 |a OLR-NBW | ||
| 995 | |2 60 |1 01 |x 0705 |a NBER | ||
| 995 | |2 70 |1 01 |x 0089 |a OLR-NBER | ||
| 998 | |2 2003 |1 01 |x DE-25 |0 08-02-24 |f 8 | ||